Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 201–300 of 1,004
Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome
Cui, Y., Shi, Y., Cui, L., Han, T., Gao, X., & Chen, Z. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.03.032 · Cited by 88
Kahal, H., Kyrou, I., Uthman, O. A., Brown, A., Johnson, S., Wall, P. D. H., Metcalfe, A., Parr, D. G., Tahrani, A. A., & Randeva, H. S. (2020) · Sleep and Breathing · doi:10.1007/s11325-019-01835-1 · Cited by 87
Perspectives in polycystic ovary syndrome: From hair to eternity
Dunaif, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3780 · Cited by 87
Chang, A. Y., Lalia, A. Z., Jenkins, G. D., Dutta, T., Carter, R. E., Singh, R. J., & Nair, K. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.002 · Cited by 81
Xu, Y., Wu, Y., & Huang, Q. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4480-z · Cited by 78
“Pioglitazone was not recommended for PCOS in the clinical practice guideline of AES in 2013 [10].”
BackgroundEndocrine correlates of polycystic ovary syndrome in Pakistani women.
Akram, M., & Roohi, N. (2015) · PubMed · Cited by 86
How does obesity affect the endocrine system? A narrative review
Poddar, M., Chetty, Y., & Chetty, V. T. (2017) · Clinical Obesity · doi:10.1111/cob.12184 · Cited by 86
“The Endocrine Society Guidelines for PCOS suggest that due to the additional risks in pregnancy and an increased metabolic risk, it is pertinent to screen all PCOS patients for abdominal obesity with a measurement of waist circumference and BMI as well as screening for complications of obesity, including sleep apnoea,…”
BackgroundInfluentialBinge eating behaviours and food cravings in women with polycystic ovary syndrome
Jeanes, Y. M., Reeves, S., Gibson, E. L., Piggott, C., May, V. A., & Hart, K. H. (2017) · Appetite · doi:10.1016/j.appet.2016.11.010 · Cited by 85
Role of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis
Benham, J. L., Yamamoto, J. M., Friedenreich, C. M., Rabi, D. M., & Sigal, R. J. (2018) · Clinical Obesity · doi:10.1111/cob.12258 · Cited by 85
Pathophysiology of NASH in endocrine diseases
Gariani, K., & Jornayvaz, F. R. (2021) · Endocrine Connections · doi:10.1530/ec-20-0490 · Cited by 87
Moran, L. J., Tassone, E. C., Boyle, J., Brennan, L., Harrison, C. L., Hirschberg, A. L., Lim, S., Marsh, K., Misso, M. L., Redman, L., et al. (2020) · Obesity Reviews · doi:10.1111/obr.13046 · Cited by 84
Ding, L., Gao, F., Zhang, M., Yan, W., Tang, R., Zhang, C., & Chen, Z. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.01.020 · Cited by 85
Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents
Trent, M., & Gordon, C. M. (2020) · PEDIATRICS · doi:10.1542/peds.2019-2056j · Cited by 84
Torky, A., Sinaii, N., Jha, S., Desai, J., El‐Maouche, D., Mallappa, A., & Merke, D. P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab133 · Cited by 84
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83
“In women with PCOS exhibiting menstrual irregularity where hormonal contraceptives are either contraindicated or not tolerated, metformin is advised as second-line therapy [47].”
BackgroundKahal, H., Kyrou, I., Tahrani, A. A., & Randeva, H. S. (2017) · Clinical Endocrinology · doi:10.1111/cen.13392 · Cited by 70
“Endocrine Society, 2013 (1): We suggest screening overweight/obese adolescents and women with PCOS for symptoms suggestive of OSA and, when identified, obtaining a definitive diagnosis using polysomnography.”
BackgroundInfluentialCree-Green, M., Rahat, H., Newcomer, B. R., Bergman, B. C., Brown, M. S., Coe, G. V., Newnes, L., Garcia-Reyes, Y., Bacon, S., Thurston, J. E., et al. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00192 · Cited by 82
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Xing, C., Zhao, H., Zhang, J., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.945609 · Cited by 82
Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 83
“Therefore, metformin is considered a second-line treatment in PCOS that offers benefits for the management of menstrual and ovulatory disorders, hirsutism, and metabolic and cardiovascular disorders [209,210].”
BackgroundAcupuncture for polycystic ovarian syndrome
Lim, C. E. D., Ng, R. W., Xu, K., Cheng, N. C. L., Xue, C. C., Liu, J., & Chen, N. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007689.pub3 · Cited by 82
Qin, L., Xu, W., Li, X.-H., Meng, W., Hu, L., Luo, Z., Wang, Y., Luo, S., & Li, S. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.12.003 · Cited by 82
Circadian Rhythms Within the Female HPG Axis: From Physiology to Etiology
Shao, S., Zhao, H., Lu, Z., Lei, X., & Zhang, Y. (2021) · Endocrinology · doi:10.1210/endocr/bqab117 · Cited by 81
Kumarendran, B., Sumilo, D., O’Reilly, M. W., Toulis, K. A., Gokhale, K. M., Wijeyaratne, C. N., Coomarasamy, A., Arlt, W., Tahrani, A. A., & Nirantharakumar, K. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0693 · Cited by 66
Depression in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Dybciak, P., Raczkiewicz, D., Humeniuk, E., Powrózek, T., Gujski, M., Malecka-Massalska, T. J., Wdowiak, A., & Bojar, I. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206446 · Cited by 88
“The main clinical symptoms include irregular menstruation or lack of menstruation cycles and/or infertility [8]; acne vulgaris, androgenic alopecia, hirsutism [9]; dyslipidemia and endothelial dysfunction markers [10]; hyperinsulinemia, insulin resistance and increase in BMI [11,12].”
BackgroundTian, F., Zheng, Z., Zhang, D., He, S., & Shen, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181304 · Cited by 80
He, F., & Li, Y. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00799-9 · Cited by 81
Teede, H., Tassone, E. C., Piltonen, T., Malhotra, J., Mol, B. W., Peña, A., Witchel, S. F., Joham, A., McAllister, V., Romualdi, D., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14013 · Cited by 79
Cameron, F. J., Amin, R., de Beaufort, C., Codner, E., & Acerini, C. L. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12169 · Cited by 69
Reyes-Muñoz, E., Sathyapalan, T., Rossetti, P., Shah, M., Long, M., Buscema, M., Valenti, G., Rosa, V. L. L., Cianci, S., & Vitale, S. G. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0810-1 · Cited by 79
Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment
Tehrani, F. R., & Amiri, M. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.91554 · Cited by 79
“Since Non-Classic Congenital Adrenal Hyperplasia (NCCAH) is the most important disorder in the differential diagnosis of PCOS, all guidelines recommend screening for this disorder (12, 18).”
BackgroundMethodInfluentialAre women with polycystic ovary syndrome at increased cardiovascular disease risk later in life?
Gunning, M. N., & Fauser, B. C. J. M. (2017) · Climacteric · doi:10.1080/13697137.2017.1316256 · Cited by 71
Aromatase Inhibitors for Ovulation Induction
Palomba, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4235 · Cited by 63
“Although identifying the precise PCOS phenotypes in clinical practice when making the diagnosis is not formally recommended (5), I believe that knowing the presence/ absence of all PCOS features will help not only the scientists but also the clinicians to manage these patients correctly (4).”
BackgroundHydroalcoholic extract of flaxseed improves polycystic ovary syndrome in a rat model.
Jelodar, G., Masoomi, S., & Rahmanifar, F. (2018) · PubMed Central · doi:10.22038/ijbms.2018.25778.6349 · Cited by 78
“Various therapeutic methods such as changing of life habits, surgery and medication like clomiphene citrate, metformin, letrozole and tamoxifen have been proposed for PCOS (3).”
BackgroundEffects of Mixed of a Ketogenic Diet in Overweight and Obese Women with Polycystic Ovary Syndrome
Cincione, R. I., Losavio, F., Ciolli, F., Valenzano, A., Cibelli, G., Messina, G., & Polito, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312490 · Cited by 77
Síndrome de ovario poliquístico en la mujer adulta
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2018.11.019 · Cited by 77
Neven, A. C. H., Forslund, M., Ranasinha, S., Mousa, A., Tay, C. T., Peña, A. S., Oberfield, S. E., Witchel, S. F., Teede, H. J., & Boyle, J. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae125 · Cited by 78
Bahri Khomami, M., Boyle, J. A., Tay, C. T., Vanky, E., Teede, H. J., Joham, A. E., & Moran, L. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13579 · Cited by 65
An Update on Contraception in Polycystic Ovary Syndrome
Oguz, S. H., & Yildiz, B. O. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.958 · Cited by 76
“The guidelines do not suggest one preparation over another [21,23], given that the current evidence is not sufficient to reveal a difference in efficacy”
BackgroundLong non-coding RNAs in ovarian granulosa cells
Tu, J., Chen, Y., Li, Z., Yang, H., Chen, H., & Yu, Z. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00663-2 · Cited by 76
The inositols and polycystic ovary syndrome
Kalra, S., Kalra, B., & Sharma, J. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.189231 · Cited by 59
“While the 2013 Endocrine Society guidelines for the management of PCOS do not suggest the use of inositols,[26] there is a definite role for this upcoming therapy.”
BackgroundCree‐Green, M., Bergman, B. C., Coe, G. V., Newnes, L., Baumgartner, A. D., Bacon, S., Sherzinger, A., Pyle, L., & Nadeau, K. J. (2016) · Obesity · doi:10.1002/oby.21651 · Cited by 70
“PCOS was diagnosed per NIH criteria with adolescent adaptation: oligomenorrhea (<8 menses a year), clinical or biochemical signs of hyper-androgynism, and at least 2 years post-menarche (8).”
BackgroundMethodGLP-1 receptor agonists in the treatment of polycystic ovary syndrome
Lamos, E. M., Malek, R., & Davis, S. N. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292125 · Cited by 71
“be used in individuals with PCOS with diabetes mellitus or IGT [49].”
MethodInfluentialCardiometabolic risk in polycystic ovary syndrome
Bajuk Studen, K., & Pfeifer, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0129 · Cited by 64
Cardiometabolic risks in PCOS: a review of the current state of knowledge
Kakoly, N. S., Moran, L., Teede, H. J., & Joham, A. E. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1556094 · Cited by 79
“This is consistent with the American Diabetes Association [47] and the Endocrine Society who also recommend annual screening among women with IGT or women with PCOS with significant additional risk factors [48].”
BackgroundReproductive risk factors across the female lifecourse and later metabolic health
Nichols, A. R., Chavarro, J. E., & Oken, E. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.01.002 · Cited by 76
Wei, L., Huang, R., Li, L., Fang, C., Li, Y., & Liang, X. (2014) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-014-0319-8 · Cited by 76
Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences
Kim, J. J., & Choi, Y. M. (2019) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.14132 · Cited by 61
“An Endocrine Society Clinical Practice Guideline in the USA even defined a score of 8–15 as mild hirsutism.(5) However, in Asian women, a cutoff score of 8 might be inappropriate for defining hirsutism (Table 1).”
BackgroundGanie, M. A., Sahar, T., Rashid, A., Wani, I. A., Nisar, S., Sathyapalan, T., Vishnubhatla, S., Ramakrishnan, L., Parvez, T., & Geer, M. I. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00699 · Cited by 75
Increased serum circulating asprosin levels in children with obesity
Silistre, E. S., & Hatipoğlu, H. U. (2020) · Pediatrics International · doi:10.1111/ped.14176 · Cited by 75
Chang, C. L., Huang, S. Y., Soong, Y. K., Cheng, P. J., Wang, C.-J., & Liang, I. T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1180 · Cited by 65
Puberty and its disorders in the female
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00024-x · Cited by 74
The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents
Khashchenko, K. E. P., Uvarova, E. V., Vysokikh, M. Y., Ivanets, T. Y., Krechetova, K. L. V., Tarasova, N. V., Sukhanova, I. A., Шапиевна, М. Ф., Borovikov, B. P. I., Balashov, I. S., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061831 · Cited by 74
“adolescence with transabdominal approach is complicated, particularly in obese patients [10,11].”
BackgroundMethodTao, T., Zhang, Y., Zhu, Y.-C., Fu, J.-R., Wang, Y.-Y., Cai, J., Ma, J.-Y., Xu, Y., Gao, Y.-N., Sun, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa692 · Cited by 62
Hirsutism: diagnosis and treatment
Hohl, A., Ronsoni, M. F., & de Oliveira, M. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000002923 · Cited by 74
“However, if there is progression of hirsutism during therapy, repeated biochemical evaluation is warranted (15,24).”
BackgroundCasarini, L., & Brigante, G. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2703 · Cited by 65
Polycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72
Polycystic Ovary Syndrome in Adolescence
Deans, R. (2019) · Medical Sciences · doi:10.3390/medsci7100101 · Cited by 72
Goh, J. E., Farrukh, M. J., Keshavarzi, F., Yap, C. S., Saleem, Z., Salman, M., Ramatillah, D. L., Goh, K. W., & Ming, L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985588 · Cited by 73
Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman
Hirschberg, A. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac673 · Cited by 77
Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies
Chaudhuri, A. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100480 · Cited by 74
Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature
Palomba, S., Colombo, C., Busnelli, A., Caserta, D., & Vitale, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1251866 · Cited by 73
Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis
Fazelian, S., Rouhani, M. H., Saraf‐Bank, S., & Amani, R. (2017) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2017.04.008 · Cited by 72
Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum
Prosperi, S., & Chiarelli, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1669716 · Cited by 72
Bui, H. N., Sluss, P. M., Hayes, F. J., Blincko, S., Knol, D. L., Blankenstein, M. A., & Heijboer, A. C. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.08.019 · Cited by 71
Samimi, M., Zarezade Mehrizi, M., Foroozanfard, F., Akbari, H., Jamilian, M., Ahmadi, S., & Asemi, Z. (2017) · Clinical Endocrinology · doi:10.1111/cen.13288 · Cited by 59
Peng, F., Hu, Y., Peng, S., Zeng, N., & Shi, L. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2034933 · Cited by 71
“Metformin (MTF) is a thiazolidinedione derivative; it increases insulin sensitivity and is an agent of choice for treating PCOS [8].”
BackgroundHyperandrogenism in Women with Polycystic Ovarian Syndrome: Pathophysiology and Controversies
Kanbour, S., & Dobs, A. S. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0020 · Cited by 70
“53”
Evidence-based approach to cutaneous hyperandrogenism in women
Schmidt, T. H., & Shinkai, K. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.026 · Cited by 70
“VOLUME jj, NUMBER j Schmidt and Shinkai 3 Acromegaly New-onset diabetes, hypertension, diffuse arthralgias, and elevated random serum IGF-1211 Coarse facial features 0.004%-0.03% in Unselected patients212-214; 0.3% in women with clinical hyperandrogenism66 Exogenous androgens Suggestive medication history, performance…”
BackgroundInfluentialIsmayilova, M., & Yaya, S. (2022) · BMC Women's Health · doi:10.1186/s12905-022-01630-3 · Cited by 68
“Several international evidence-based guidelines and reviews [2, 20, 22, 33, 53] have been established for the diagnosis and management of PCOS which can be consulted by clinicians in practice.”
BackgroundDokras, A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.027 · Cited by 69
Lewandowski, K. C., Skowrońska‐Jóźwiak, E., Łukasiak, K., Gałuszko, K., Dukowicz, A., Cedro, M., & Lewiñski, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.82672 · Cited by 70
“There is however universal agreement that all women with PCOS should be assessed for abnormalities typical for the metabolic syndrome, including lipids and oral glucose tolerance test [13].”
Exercise and insulin resistance in PCOS: muscle insulin signalling and fibrosis
Stepto, N. K., Hiam, D., Gibson‐Helm, M. E., Cassar, S., Harrison, C. L., Hutchison, S. K., Joham, A. E., Canny, B. J., Moreno‐Asso, A., Strauss, B. J., et al. (2020) · Endocrine Connections · doi:10.1530/ec-19-0551 · Cited by 71
Han, Y., Wu, H., Sun, S., Zhao, R., Deng, Y., Zeng, S., & Chen, J. (2023) · Nutrients · doi:10.3390/nu15092230 · Cited by 69
Steroid hormone profiling in obese and nonobese women with polycystic ovary syndrome
Deng, Y., Zhang, Y., Li, S., Zhou, W., Ye, L., Wang, L., Tao, T., Gu, J., Yang, Z., Zhao, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14534-2 · Cited by 69
Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome
Tosi, F., Fiers, T., Kaufman, J.-M., Dall'Alda, M., Moretta, R., Giagulli, V. A., Bonora, E., & Moghetti, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2807 · Cited by 67
Fraser, G. L., Obermayer-Pietsch, B. M., Laven, J. S. E., Griesinger, G., Pintiaux, A., Timmerman, D., Fauser, B. C. J. M., Lademacher, C., Combalbert, J., Hoveyda, H. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab320 · Cited by 69
“Metformin improves insulin sensitivity and is used in conjunction with dietary advice as additional therapy in women with PCOS who present with abnormal glucose tolerance or type 2 diabetes (5, 22).”
BackgroundShi, Q., Liu, R. R., & Chen, L. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12645 · Cited by 67
Farland, L. V., Stern, J. E., Liu, C., Cabral, H., Coddington, C. C., Diop, H., Dukhovny, D., Hwang, S. S., & Missmer, S. A. (2022) · Human Reproduction · doi:10.1093/humrep/deac210 · Cited by 70
Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
Khani, B., Mardanian, F., & Fesharaki, S. J. (2017) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_644_16 · Cited by 59
Liu, C., Feng, G., Huang, W., Wang, Q., Yang, S., Tan, J., Fu, J., & Liu, D. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1332174 · Cited by 67
“As one of the common endocrine disorders, polycystic ovary syndrome (PCOS) is a clinical syndrome characterized as persistent anovulation, hyperandrogenism, polycystic ovary like changes, and insulin resistance [1,2].”
Choudhary, A., Jain, S., & Chaudhari, P. (2017) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20175010 · Cited by 67
Cioana, M., Deng, J., Nadarajah, A., Hou, M., Qiu, Y., Chen, S. S. J., Rivas, A., Banfield, L., Alfaraidi, H., Alotaibi, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47454 · Cited by 52
Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome
Persson, S., Elenis, E., Türkmen, Ş., Kramer, M. S., Yong, E., & Poromaa, I. S. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.04.018 · Cited by 66
Patton, L., Ricolfi, L., Bortolon, M., Gabriele, G., Zolesio, P., Cione, E., & Cannataro, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031599 · Cited by 67
“The diagnosis was made according to the Rotterdam criteria [52,53] in the presence of at least two of the following parameters: clinical (hirsutism, acne, alopecia) and/or biochemical hyperandrogenism (biochemical hyperandrogenism refers to elevated total testosterone or FAI), chronic…”
MethodNew guidelines for the diagnosis and treatment of PCOS
Orio, F., & Palomba, S. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.248 · Cited by 66
Metabolic syndrome, diet and exercise
Sousa, S. M. C. D., & Norman, R. J. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.01.006 · Cited by 71
Acupuncture for polycystic ovarian syndrome: A systematic review and meta-analysis
Jo, J., Lee, Y. J., & Lee, H. (2017) · Medicine · doi:10.1097/md.0000000000007066 · Cited by 66
MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease
Μacut, D., Antić, I. B., Bjekić-Macut, J., & Τζιόμαλος, Κ. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1063 · Cited by 67
Saleem, F., & Rizvi, S. W. (2017) · Cureus · doi:10.7759/cureus.1844 · Cited by 52
“The Endocrine Society’s clinical practice guidelines define PCOS (using the Rotterdam criteria) as the presence of two or more of the following: hyperandrogenism, ovulatory dysfunction, or polycystic ovaries, whereas the disorders that mimic the clinical features of PCOS are excluded [1-2].”
InfluentialCardiometabolic Risk in PCOS: More than a Reproductive Disorder
Torchen, L. C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0956-2 · Cited by 65
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Polycystic ovary syndrome and its management: In view of oxidative stress
Bhattacharya, K., Dey, R., Sen, D., Paul, N., Basak, A. K., Purkait, M. P., Shukla, N., Chaudhuri, G. R., Bhattacharya, A., Maiti, R., et al. (2024) · BioMolecular Concepts · doi:10.1515/bmc-2022-0038 · Cited by 67
“The Rotterdam criteria are widely acknowledged by scienti fi c associations and health authorities as the primary classi fi cation system for PCOS [3,11,12].”
BackgroundGreenwood, E. A., Noel, M., Kao, C., Shinkai, K., Pasch, L. A., Cedars, M. I., & Huddleston, H. G. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.10.020 · Cited by 65
Pathogenesis and Consequences of Disordered Sleep in PCOS
Sam, S., & Ehrmann, D. A. (2019) · Clinical Medicine Insights: Reproductive Health · doi:10.1177/1179558119871269 · Cited by 51
Self-citationAntidiabetic medication use during pregnancy: an international utilization study
Cesta, C. E., Cohen, J. M., Pazzagli, L., Bateman, B. T., Bröms, G., Einarsdóttir, K., Furu, K., Havard, A., Heino, A., Hernández–Díaz, S., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000759 · Cited by 65
Physiology and Disorders of Puberty
Styne, D. M., & Grumbach, M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00025-3 · Cited by 67
Qin, L., Huang, C., Yan, X., Wang, Y., Li, Z., & Wei, X. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0004 · Cited by 64
“Worryingly, PCOS is a common cause of female infertility, accounting for 75% of cases involving anovulatory infertility [3].”
BackgroundMukherjee, A. G., Wanjari, U. R., Kannampuzha, S., Murali, R., Namachivayam, A., Ganesan, R., Dey, A., Babu, A., Renu, K., Vellingiri, B., et al. (2023) · Metabolites · doi:10.3390/metabo13010129 · Cited by 67
“Polycystic ovary syndrome (PCOS), the most common cause of female endocrine infertility, is characterized by increased ovarian androgen biosynthesis, anovulation, and, as previously stated, infertility [1,2].”
BackgroundInfluentialMulvagh, S. L., Mullen, K., Nerenberg, K. A., Kirkham, A. A., Green, C. R., Dhukai, A. R., Grewal, J., Hardy, M., Harvey, P., Ahmed, S. B., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.09.013 · Cited by 66
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.